Regulatory Update

New peptides on the horizon:
what the 2026 FDA policy means

By Dr. Christina Ganeshalingam November 19, 2026 5 min read

For years, some of the most talked-about peptides in regenerative and longevity medicine have existed in a regulatory gray zone. A policy change this fall begins to clear a path — carefully, and with important limits worth understanding.

If you follow the peptide space, you've probably heard names like BPC-157 and TB-500 discussed for recovery, or MOTS-c and epitalon for metabolic and longevity support. Until recently, these couldn't be legally compounded for patients in the United States. On October 28, 2026, that began to change.

What actually changed

The U.S. Department of Health and Human Services issued a limited enforcement-discretion policy covering six specific peptides. In plain terms: the FDA has said it will not take enforcement action against state-licensed pharmacies and physicians who compound these six peptides — provided a detailed set of conditions is met.

The six peptides covered

PeptideCommonly discussed for
BPC-157Tissue repair, gut health, recovery
TB-500Soft-tissue recovery, inflammation
KPVInflammation, gut and skin support
MOTS-cMetabolic and mitochondrial function
SemaxCognitive and neurological support
EpitalonLongevity and cellular aging

The uses listed above reflect how these peptides are studied and discussed. They are not FDA-approved indications, and the evidence base varies considerably from one peptide to the next.

The conditions matter as much as the list

The policy only applies when strict requirements are met. A few that are worth knowing as a patient:

Why a careful approach still matters

A path to legal compounding is not the same as a green light to use these peptides casually. Enforcement discretion is temporary and conditional. The underlying science still ranges from promising to preliminary depending on the compound, and these are still prescription therapeutics that require physician evaluation, appropriate candidacy, lab work, and monitoring.

Where PeplivMD stands. Our current offerings focus on well-established, FDA-approved and widely-used therapies — GLP-1 medications, sermorelin, tesamorelin, and PT-141. We are following the evolving regulatory landscape closely.

We intend to offer these additional peptides once they are available to us through compliant 503A compounding pharmacies, under the conditions the policy requires. As with every therapy we provide, each will be prescribed individually and evidence-first — only when it's clinically appropriate for the patient in front of us.

What happens next

The enforcement-discretion policy is an interim step, not the finish line. The FDA still has to complete formal notice-and-comment rulemaking before any of these peptides are permanently added to the compounding list — and that process includes further advisory-committee review. The written-comment period on the interim policy closed in mid-November 2026, and the broader rulemaking will unfold over the coming months.

We'll keep our patients and waitlist informed as things develop. If a peptide moves from "pending" to "appropriate to offer," you'll hear it from us with the clinical context to go with it.

Want updates as this develops?

Join the PeplivMD waitlist — we'll keep you posted as new therapies become available.

Join the Waitlist

Sources

This article is for general informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The peptides discussed are not FDA-approved, and the enforcement-discretion policy described is interim and subject to change. Nothing here is an offer to prescribe or a representation that any specific therapy is currently available through PeplivMD. Peptide therapies require a valid physician–patient relationship, individual evaluation, and prescription. PeplivMD is a program of New York CMG Medical PLLC.